Form 4: Cryo-Cell Co-CEO Portnoy Boosts Stake with Stock Buys
Insider Transaction Report
Cryo-Cell International Co-CEO David Portnoy reported acquiring additional common stock and detailed his extensive beneficial ownership, including various stock options.
Summary
- David Portnoy, Chairman and Co-CEO of Cryo-Cell International Inc. (CCEL), reported acquiring additional shares of common stock.
- On October 31, 2025, Portnoy acquired 4,666 shares of common stock at a price of $4.45 per share.
- On November 4, 2025, he acquired an additional 5,000 shares of common stock at a weighted average price of $4.40 per share.
- Following these transactions, Portnoy directly beneficially owns 837,010 shares of common stock.
- His indirect beneficial ownership includes 161,833 shares held by PartnerCommunity, Inc., 164,182 shares in a 401K, 268,878 shares in an IRA, 107,403 shares by his spouse, 33,874 shares as custodian for his son (across three accounts), 57,306 shares by uTIPu, Inc., and 59,027 shares by Mayim Limited Partnership.
- Portnoy also holds several stock options with various exercise prices and vesting schedules, totaling 530,000 derivative securities.
- One notable stock option for 280,000 shares, granted on December 22, 2021, will vest immediately if the company's common stock reaches $25.00 per share during its seven-year term.
Sentiment
Score: 7
Explanation: The sentiment is positive due to significant insider buying by a key executive, which typically signals confidence in the company's future performance and valuation.
Positives
- Increased insider ownership by a key executive (Chairman, Co-CEO) signals confidence in the company's future prospects.
- The acquisitions were open market purchases, indicating a direct investment decision by management.
Risks
- No specific risks related to company operations or financial health are disclosed in this insider transaction report.
Future Outlook
The filing indicates future vesting events for several tranches of stock options held by David Portnoy, with specific dates extending through January 2027. A significant portion of options (280,000 shares) has a performance-based vesting condition, triggering immediate vesting if the company's common stock reaches $25.00 per share during the option term.
Management Comments
- This Form 4 filing represents a direct action by David Portnoy, Chairman and Co-CEO, to increase his beneficial ownership in Cryo-Cell International Inc., signaling his personal investment and confidence in the company.
Industry Context
This filing is a standard insider transaction report (Form 4) within the U.S. regulatory framework. Insider buying, particularly by a high-ranking executive, is often viewed by the market as a positive signal, suggesting management believes the company's stock is undervalued or expects positive future developments. This is a common occurrence across all industries, including the biotechnology and stem cell banking sector where Cryo-Cell operates.
Related Party Transactions
- David Portnoy's indirect beneficial ownership includes shares held by entities where he holds significant influence or control: PartnerCommunity, Inc. (161,833 shares), uTIPu, Inc. (57,306 shares), and Mayim Limited Partnership (59,027 shares). These holdings represent transactions or arrangements with entities closely associated with the reporting person.
Stakeholder Impact
- Shareholders may view the increased insider ownership as a positive indicator of management's belief in the company's value and future prospects, potentially boosting investor confidence.
- Employees may perceive this as a sign of stability and positive outlook from leadership.
Next Steps
- Monitoring the vesting of various stock options held by David Portnoy on their respective scheduled dates.
- Observing if Cryo-Cell International's common stock price reaches $25.00 per share, which would trigger immediate vesting for 280,000 stock options.
Key Dates
| Date | Description |
|---|---|
| 08/30/2019 | Grant date for 26,243 stock options with an exercise price of $7.53. |
| 12/20/2019 | Grant date for 23,636 stock options with an exercise price of $7.28. |
| 12/22/2021 | Grant date for 280,000 stock options with an exercise price of $12.27, vesting immediately if stock reaches $25.00. |
| 12/23/2022 | Grant date for 50,000 stock options with an exercise price of $4.30. |
| 01/03/2023 | Grant date for 50,000 stock options with an exercise price of $4.77, with staggered vesting. |
| 12/22/2023 | Grant date for 50,000 stock options with an exercise price of $6.47, with staggered vesting. |
| 01/02/2024 | Vesting date for 8,749 stock options from the 01/03/2023 grant. |
| 12/22/2024 | Vesting date for 1/3 of stock options from the 12/22/2023 grant. |
| 01/21/2025 | Grant date for 50,000 stock options with an exercise price of $8.08, with staggered vesting. |
| 01/02/2025 | Vesting date for 21,000 stock options from the 01/03/2023 grant. |
| 10/31/2025 | Acquisition of 4,666 shares of common stock at $4.45. |
| 11/04/2025 | Acquisition of 5,000 shares of common stock at a weighted average price of $4.40. |
| 12/22/2025 | Vesting date for 1/3 of stock options from the 12/22/2023 grant. |
| 01/02/2026 | Vesting date for 11,501 stock options from the 01/03/2023 grant. |
| 01/21/2026 | Vesting date for 1/3 of stock options from the 01/21/2025 grant. |
| 01/21/2027 | Vesting date for 1/3 of stock options from the 01/21/2025 grant. |
| 12/23/2027 | Expiration date for 50,000 stock options granted on 12/23/2022. |
| 01/03/2028 | Expiration date for 50,000 stock options granted on 01/03/2023. |
| 12/22/2028 | Expiration date for 280,000 stock options granted on 12/22/2021 and 50,000 stock options granted on 12/22/2023. |
| 08/30/2029 | Expiration date for 26,243 stock options granted on 08/30/2019. |
| 12/20/2029 | Expiration date for 23,636 stock options granted on 12/20/2019. |
| 01/21/2030 | Expiration date for 50,000 stock options granted on 01/21/2025. |
Recommendation
holdThe insider buying by a high-ranking executive is a positive signal, indicating management's confidence in the company's future. While not a standalone 'strong buy' catalyst, it provides a favorable backdrop for existing shareholders and warrants a 'hold' recommendation, suggesting investors maintain their positions and monitor future developments.
Keywords
Cryo-Cell International, CCEL, David Portnoy, Insider Buying, Form 4, Stock Acquisition, Beneficial Ownership, Stock Options, Biotechnology, Stem Cell Banking
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.